News

AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...

Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.

AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Both of these stocks pay more than double the S&P 500 average of 1.1%.

Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.

The pharmaceutical company hopes that another big-time acquisition will pay off.

For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.

Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

The stock is up just 8% this year and could prove to be an undervalued buy.

Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.

Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.

AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure o

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...

If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic

Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.

JEPI's fat monthly yield has made it a retiree favorite, but a smaller rival running a completely different options playbook has quietly compounded far more wealth over the same period without sacrificing the monthly income routine investors depend on.

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

There is no end in sight for the drugmaker's dividend growth streak.

The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.

AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]